Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

141.10 2.33 +1.68%
Market cap
$9.6B
P/E
26.4×
Fwd P/E
24.7×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
716.10 953.40 704.20 674.70 791.60 947.60 376.10 288.90 440.06 298.57
Receivables
516.90 365.50 359.70 205.60 161.00 95.30 69.30 76.70 53.37 28.80
Inventory
452.60 430.40 402.60 346.80 303.20 154.30 101.00 71.40 33.79 35.51
Total current assets
1,914.00 1,891.30 1,582.90 1,314.00 1,329.80 1,248.70 591.00 461.30 537.17 369.96
Property, Plant, Equpment (Net)
819.50 723.10 664.90 599.90 536.50 478.70 399.40 258.40 107.86 44.75
Long-Term Investments
— — — — — — 58.40 140.80 125.55 —
Goodwill and Intangible Assets (Total)
168.70 150.00 150.40 127.20 76.40 68.50 53.00 50.00 44.19 41.72
Long Term Assets (Tax, Deferred)
82.40 141.80 1.80 — — — — — — —
Long-term assets (Other)
205.80 181.50 188.20 210.00 106.10 77.00 41.10 18.20 1.97 0.22
Total non-current assets
1,276.40 1,196.40 1,005.30 937.10 719.00 624.20 551.90 467.40 279.57 86.69
Total Assets
3,190.40 3,087.70 2,588.20 2,251.10 2,048.80 1,872.90 1,142.90 928.70 816.74 456.65
Accounts Payable
75.00 19.80 19.20 30.80 37.70 54.10 54.50 25.50 24.41 13.16
Accrued Expenses
586.70 424.90 382.60 306.40 166.00 138.10 103.20 90.20 59.26 41.23
Current Part of Debt
18.40 83.80 49.40 27.50 25.10 15.60 4.00 — — 0.00
Current Revenue (Deferred)
— — — — — — — 1.18 2.36 1.31
Total current liabilities
680.10 528.40 451.20 364.70 228.80 207.80 157.70 115.70 86.03 55.70
Long Term Debt (Total)
930.80 1,296.10 1,366.40 1,374.30 1,248.80 1,043.70 887.90 592.00 566.17 332.77
Non-current Liabilities (Other)
64.40 51.70 37.90 35.70 14.90 17.80 21.40 8.90 6.03 5.03
Total non-current liabilities
995.20 1,347.80 1,404.30 1,410.00 1,263.70 1,061.50 909.30 600.90 572.20 337.80
Total liabilities
1,675.20 1,876.10 1,855.50 1,774.70 1,492.50 1,269.30 1,067.00 716.60 658.23 393.50
Additional Paid In Capital
1,274.90 1,184.40 1,102.60 1,040.60 1,207.90 1,264.30 749.00 898.50 866.21 744.24
Common Stock (Net)
0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.06 0.06
Retained Earnings
287.40 40.30 (378.00) (584.30) (649.50) (666.30) (672.00) (683.60) (707.25) (680.42)
Treasury Stock
60.40 — — — — — — — — —
Common Equity (Total)
1,515.30 1,211.60 732.70 476.40 556.30 603.60 75.90 212.10 158.52 63.15
Shareholders Equity (Total)
1,515.20 1,211.60 732.70 476.40 556.30 603.60 75.90 212.10 158.52 63.15
Shareholders Equity and Liabilities (Total)
3,190.40 3,087.70 2,588.20 2,251.10 2,048.80 1,872.90 1,142.90 928.70 816.74 456.65
Shares (Common)
70.39 70.20 69.91 69.51 69.18 66.02 62.69 59.19 58.32 57.46
Shareholders Equity (Tangible)
1,346.50 1,061.60 582.30 349.20 479.90 535.10 22.90 162.10 114.33 21.43
Net Debt
233.10 426.50 711.60 727.10 482.30 111.70 515.80 303.10 126.12 34.20
Total Debt
949.20 1,379.90 1,415.80 1,401.80 1,273.90 1,059.30 891.90 592.00 566.17 332.77

Fold the line items

In millions of $ except per-share values · columns are period end dates